Patents Examined by Tamthom T. Ngo
-
Patent number: 5892046Abstract: The present invention relates to trifluoromethylpyridone-based methine and azamethine dyes of the formula I ##STR1## a process for their thermal transfer, a process for dyeing or printing synthetic materials and their use.Type: GrantFiled: April 24, 1997Date of Patent: April 6, 1999Assignee: BASF AktiengesellschaftInventors: Clemens Grund, Helmut Reichelt, Andreas Johann Schmidt, Stefan Beckmann
-
Patent number: 5889010Abstract: Pharmaceutically active benzimidazole derivatives are disclosed comprising compounds of the formula: ##STR1## particularly wherein X is nitrogen, R.sup.1 is phenyl or heteroaryl, and one of R.sup.2 or R.sup.3 is hydroxy.Type: GrantFiled: January 31, 1997Date of Patent: March 30, 1999Assignee: Pfizer Inc.Inventors: William S. Faraci, Anton F. J. Fliri, Brian T. O'Neill, Mark A. Sanner, Stevin H. Zorn
-
Patent number: 5886014Abstract: Compounds of formula (I): ##STR1## ?wherein: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethlyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5!; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.Type: GrantFiled: May 31, 1996Date of Patent: March 23, 1999Assignee: Sankyo Company, LimitedInventors: Takashi Fujita, Kunio Wada, Minoru Oguchi, Hiroaki Yanagisawa, Koichi Fujimoto, Toshihiko Fujiwara, Hiroyoshi Horikoshi, Takao Yoshioka
-
Patent number: 5885991Abstract: Disclosed are thiocyanomethyloxy(or thiocyanomethylthio)-1,2,3-benzatriazin-4(3H)-one compounds corresponding to one of the formulae: ##STR1## wherein Z represents oxygen or sulfur; X represents --C1, --F, --I, C.sub.1 -C.sub.7 straight or branched chain alkyl, C.sub.1 -C.sub.7 straight or branched chain alkoxy, --CF.sub.3, --OCF.sub.3, --CN, --COOR wherein R is C.sub.1 -C.sub.7 straight or branched chain alkyl and n is an integer of from 0-4.These compounds have been found to exhibit antimicrobial and marine antifouling activity in industrial and commercial applications and compositions containing these compounds are so employed.Type: GrantFiled: June 26, 1997Date of Patent: March 23, 1999Assignee: The Dow Chemical CompanyInventors: Ravi B. Shankar, R. Garth Pews, Duane R. Romer
-
Patent number: 5883102Abstract: Compounds of formula (I) wherein: R.sup.1 and R.sup.19 independently represent hydrogen, alkyl C1-6, alkoxy C1-6, alkylthio C1-6, halogen, hydroxyl or amino;R.sup.2 represents H or alkyl;R.sup.3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O,N, and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1-6, alkoxy C1-6, haologen, hydroxyl, alkylthio C1-6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group --(CH.sub.2).sub.c NHCO.sub.2 R.sup.10, a group --(CH.sub.2).sub.c NR.sup.5 R.sup.6, or a group --CO.sub.2 R.sup.11 ; or R.sup.3 represents hydrogen or alkyl C1-8, which alkyl group may be optionally substituted by amino or a group --NHCO.sub.2 R.sup.10 ;R.sup.4 represents hydrogen or alkyl C1-6; orR.sup.3 and R.sup.4 taken together represent a group (CH.sub.2).sub.a Z(CH.sub.2).sub.Type: GrantFiled: March 3, 1997Date of Patent: March 16, 1999Assignee: Astra Pharmaceuticals LimitedInventors: Peter Hamley, Austen Pimm, Alan Tinker, Haydn Beaton, Thomas McInally
-
Patent number: 5883090Abstract: This invention relates to pyridizinone derivatives of formula I ##STR1## wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.Type: GrantFiled: June 6, 1997Date of Patent: March 16, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Dieter Dorsch, Mathias Osswald, Werner Mederski, Claudia Wilm, Claus Jochen Schmitges, Maria Christadler
-
Patent number: 5880151Abstract: The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.Type: GrantFiled: July 18, 1997Date of Patent: March 9, 1999Assignee: Tularik Inc.Inventors: Julio Cesar Medina, David Louis Clark, John A. Flygare, Terry J. Rosen, Bei Shan
-
Patent number: 5877138Abstract: A scatterable dry cleaning composition containing: (a) cellulose powder adsorbent; (b) ground polyurethane foam absorbent; and (c) water.Type: GrantFiled: October 11, 1996Date of Patent: March 2, 1999Assignee: Henkel Kommanditgesellschaft auf AktienInventors: Alexander Ditze, Bernd-Dieter Holdt, Thomas Hahn, Franz Kresse, Theo Fleckenstein
-
Patent number: 5874573Abstract: This invention involves synthesis and use of a class of compounds with chelation affinity and selectivity for first transition series elements. Administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease in the in vivo bioavailability of first transition series elements and/or removal from the body of first transition series elements and elements with similar chemical properties. These characteristics make such compounds useful in the management of diseases associated with a bodily excess of first transition series elements and elements with similar chemical properties. This invention demonstrates that such compounds inhibit mammalian, bacterial, and fungal cell replication and are therefore useful in the treatment of neoplasia, infection, inflammation, immune response, and in termination of pregnancy.Type: GrantFiled: June 24, 1996Date of Patent: February 23, 1999Assignee: Concat, Inc.Inventors: Harry S Winchell, Joseph Y Klein, Elliot D Simhon, Rosa L Cyjon, Ofer Klein, Haim Zaklad
-
Patent number: 5874428Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: March 28, 1996Date of Patent: February 23, 1999Assignee: Novo Nordisk AlsInventors: Florenzio Zaragossa D.o slashed.rwald, Knud Erik Andersen, Rolf Hohlweg, Peter Madsen, Tine Krogh J.o slashed.rgensen, Uffe Bang Olsen, Henrik Sune Andersen, Svend Treppendahl, Polivka Zdenek, Silhankova Alexandra, Sindelar Karel
-
Patent number: 5874438Abstract: The present invention relates to 2,2'-bridged bis-2,4-diaminoquinazolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides processes for the preparation of the compounds of the formula (I), their use for the preparation of drugs, and drugs containing said compounds.Type: GrantFiled: October 11, 1996Date of Patent: February 23, 1999Assignee: Bayer AktiengesellschaftInventors: Rudolf Schohe-Loop, Peter-Rudolf Seidel, William Bullock, Walter Hubsch, Achim Feurer, Hans-Georg Lerchen, Georg Terstappen, Joachim Schuhmacher, Franz-Josef van der Staay, Bernard Schmidt, Richard J. Fanelli, Jane C. Chisholm, Richard T. McCarthy
-
Patent number: 5874441Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.Type: GrantFiled: March 18, 1997Date of Patent: February 23, 1999Assignee: DuPont Pharmaceuticals CompanyInventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
-
Patent number: 5869659Abstract: The present invention relates to heteroatom-containing cyclopentanopyridyl-oxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.Type: GrantFiled: January 13, 1997Date of Patent: February 9, 1999Assignee: Bayer AktiengesellschaftInventors: Andreas Stolle, Dieter Habich, Bernd Riedl, Martin Ruppelt, Stephen Bartel, Walter Guarnieri, Hanno Wild, Rainer Endermann, Hein-Peter Kroll
-
Patent number: 5869490Abstract: The compounds of formula I: ##STR1## wherein X is H.sub.2 or O;R.sup.1 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido;Z is defined by ##STR2## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the specification; or a pharmaceutically acceptable salt thereof, are useful for the treatment of brain dopamine dysregulation.Type: GrantFiled: October 9, 1997Date of Patent: February 9, 1999Assignee: American Home Products CorporationInventor: Gary Paul Stack
-
Patent number: 5866568Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: June 4, 1996Date of Patent: February 2, 1999Assignee: Zeneca LimitedInventors: Robert Hugh Bradbury, Roger John Butlin, Roger James
-
Patent number: 5863918Abstract: A compound or the formula: ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy,R.sup.3 is hydrogen, hydroxy, protected hydroxy, etc.,R.sup.4 is hydrogen or halogen,A.sup.1 is lower alkylene,A.sup.2 is bond or lower alkylene,--R.sup.5 is ##STR2## (in which R.sup.6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc., and ##STR3## etc., and a pharmaceutically acceptable salt thereof which are useful as medicaments.Type: GrantFiled: February 23, 1998Date of Patent: January 26, 1999Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kiyoshi Taniguchi, Masanobu Nagano, Kouji Hattori, Kazunori Tsubaki, Osamu Okitsu, Seiichiro Tabuchi
-
Patent number: 5861401Abstract: The invention concerns pharmaceutically useful N-heterocyclyl sulphonamide derivatives, their pharmaceutically acceptable salts, processes for their manufacture, their use for antagonising one or more actions of endothelin in a human or other warm-blooded animal, their use in methods of treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role.Type: GrantFiled: September 30, 1996Date of Patent: January 19, 1999Assignee: Zeneca LimitedInventor: Robert Hugh Bradbury
-
Patent number: 5859006Abstract: A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl;R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; andR.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain.Type: GrantFiled: July 16, 1996Date of Patent: January 12, 1999Assignee: ICOS CorporationInventor: Alain Claude-Marie Daugan
-
Patent number: 5859008Abstract: Arylalkyl diazinone derivatives of the formula I ##STR1## and their physiologically acceptable salts, in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, B, Q and X have the meanings indicated in claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of inflammatory processes and also of allergies, asthma and autoimmune disorders.Type: GrantFiled: September 13, 1996Date of Patent: January 12, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Rochus Jonas, Michael Wolf, Norbert Beier
-
Patent number: 5859007Abstract: Benzo?b!?1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.Type: GrantFiled: November 14, 1996Date of Patent: January 12, 1999Assignee: Glaxo Wellcome Inc.Inventors: Christopher Joseph Aquino, Marcus Brackeen, Milana Dezube, Brad Richard Henke, Gavin Charles Hirst, Peter Walter Jeffs, Tanya Momtahen, Elizabeth Ellen Sugg, Edward Martin Suh, Timothy Mark Willson